Revance Therapeutics Inc (RVNC)

[rolvram]

Campbell & CO Investment Adviser LLC acquired a new stake in Revance Therapeutics, Inc. (NASDAQ:RVNC - Get Rating) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 28,390 shares of the biopharmaceutical company's stock, valued at approximately $524,000.

Get Revance Therapeutics alerts:
Enter Your Email Address
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
A number of other institutional investors have also recently made changes to their positions in the stock. Two Sigma Investments LP increased its stake in shares of Revance Therapeutics by 20.4% in the fourth quarter. Two Sigma Investments LP now owns 1,351,154 shares of the biopharmaceutical company's stock worth $24,942,000 after buying an additional 229,331 shares during the period. Granahan Investment Management LLC increased its position in shares of Revance Therapeutics by 42.1% in the fourth quarter. Granahan Investment Management LLC now owns 348,064 shares of the biopharmaceutical company's stock valued at $6,425,000 after acquiring an additional 103,147 shares during the period. Engineers Gate Manager LP purchased a new position in shares of Revance Therapeutics in the fourth quarter valued at about $619,000. Charles Schwab Investment Management Inc. raised its stake in shares of Revance Therapeutics by 6.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 606,618 shares of the biopharmaceutical company's stock valued at $11,198,000 after acquiring an additional 38,059 shares during the last quarter. Finally, Deutsche Bank AG boosted its holdings in shares of Revance Therapeutics by 389.6% during the fourth quarter. Deutsche Bank AG now owns 158,319 shares of the biopharmaceutical company's stock worth $2,923,000 after purchasing an additional 125,982 shares during the period. Hedge funds and other institutional investors own 82.68% of the company's stock.